RNA Outsourcing Videos

  1. Maintaining A State Of Control: EM And DES In Biopharma 4/9/2026

    Partner with a proven team to streamline your facility validation and environmental monitoring programs with flexible, cGMP-compliant services and reliable on-site collection.

  2. Mastering The Path: Developing Processes For Successful Clinical-Grade mRNA Manufacturing 9/23/2026

    Discover strategies to optimize mRNA manufacturing, improve yield and full-length products, and enable scalable production of mRNA and saRNA therapies.

  3. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  4. The Latest And Greatest Technological Innovations In mRNA-LNP Production 2/10/2025

    In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.

  5. No Cells, No Limits To DNA Production: Inside Synthetic DNA 6/12/2025

    Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.

  6. Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems 2/13/2025

    Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

  7. Optimizing Viability And Standardization For Clinical Excellence 10/2/2024

    Explore how IntegriCell™ delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.

  8. A Deeper Dive On Mitigating Financial Risk Before Selecting A Vendor 1/23/2024

    In part two of this webinar series, presenters focus on avoiding potential risks, such as unexpected budget changes and unplanned change orders, that could jeopardize the success of a clinical trial.

  9. Must-Have CDMO Capabilities And MSA Make-Or-Breaks For mRNA-LNP Outsourcing 2/10/2025

    Three Advancing RNA Live panelists share their greatest needs in outsourcing partnerships for mRNA/RNA-LNP products and where sponsors should be the most prescriptive when drafting an MSA with an outsourcing partner.